000963 华东医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)11.64515.92514.32814.21714.754
总资产报酬率 ROA (%)7.0639.8398.7758.5908.991
投入资产回报率 ROIC (%)9.27613.04711.91611.85612.571

边际利润分析
销售毛利率 (%)33.51833.21132.40031.90330.686
营业利润率 (%)10.25810.3208.5008.1178.262
息税前利润/营业总收入 (%)10.02310.3188.6588.2458.245
净利润/营业总收入 (%)8.3948.3387.0076.7156.766

收益指标分析
经营活动净收益/利润总额(%)103.430102.585102.189103.790100.298
价值变动净收益/利润总额(%)-3.659-3.003-6.736-3.731-3.406
营业外收支净额/利润总额(%)-2.696-0.5400.377-1.001-0.997

偿债能力分析
流动比率 (X)1.5591.5261.7121.7301.671
速动比率 (X)1.2021.1801.3151.2881.242
资产负债率 (%)38.65037.79235.59338.52237.246
带息债务/全部投入资本 (%)18.94018.14313.55214.20911.904
股东权益/带息债务 (%)418.324441.461620.086578.494712.153
股东权益/负债合计 (%)156.378161.087176.469154.613164.885
利息保障倍数 (X)289.023194.19968.70939.733129.087

营运能力分析
应收账款周转天数 (天)80.82568.21364.93065.04865.453
存货周转天数 (天)62.02258.30957.58759.36460.424